Survival benefit of anti-angiogenic agents in patients with previously treated advanced gastric or gastroesophageal junction cancer: a meta-analysis

There is a debate as to whether anti-angiogenic molecular agents can produce survival benefits in patients with previously treated advanced gastric cancer (GC) or gastroesophageal junction cancer (GEJC). We performed this meta-analysis of randomized trials to evaluate the survival outcomes of an ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jung Han, Kim, Hyeong Su, Kim, Bum Jun, Jang, Hyun Joo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722584/
https://www.ncbi.nlm.nih.gov/pubmed/29228632
http://dx.doi.org/10.18632/oncotarget.18314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722584/
https://www.ncbi.nlm.nih.gov/pubmed/29228632
http://dx.doi.org/10.18632/oncotarget.18314

Ejemplares similares